Multiple myeloma: open trials in Canada

49 open trials have a site in Canada. Registry data; only the trial team decides who can take part.

NCT05552222
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Trial Treatment · Phase 3 · Janssen Research & Development, LLC
Arthur J.E. Child Comprehensive Cancer Centre, Calgary · Cross Cancer Institute, Edmonton · Lakeridge Health Oshawa, Oshawa · CHU de Quebec - L'Hôtel-Dieu de Québec, Québec · British Columbia Cancer Agency, Vancouver
Registry updated 2026-11-03
NCT07258511
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Trial Treatment · Phase 3 · Janssen Research & Development, LLC
Arthur J.E. Child Comprehensive Cancer Centre, Calgary · Queen Elizabeth II, Health Sciences Centre, Halifax · Juravinski Cancer Centre, Hamilton · London Health Sciences Centre, London · CIUSSS de l Est de l Ile de Montreal Installation Hopital Maisonneuve Rosemont, Montreal · University Health Network UHN Princess Margaret Cancer Centre, Toronto · British Columbia Cancer Agency, Vancouver
Registry updated 2026-11-03
NCT05519085
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Trial Treatment · Phase 3 · Celgene
Greenfield Park · Montreal · Québec
Registry updated 2026-10-30
NCT06106945
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
Trial Treatment · Phase 1/2 · AstraZeneca
Hamilton · Montreal · Nova Scotia · Ottawa · Toronto
Registry updated 2026-10-30
NCT06615479
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Trial Treatment · Phase 3 · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Arthur J.E. Child Comprehensive Cancer Centre, Calgary · QEII Health Sciences Centre, Victoria General Site, Halifax · Hamilton Health Sciences-Juravinski Cancer Centre, Hamilton · CIUSSS de l'Est-de-l'Île-de-Montréal, Montreal · Vancouver General Hospital, Vancouver
Registry updated 2026-10-29
NCT00900198
Collection of Tissue Samples for Cancer Research
Research · National Cancer Institute (NCI)
Princess Margaret Hospital Cancer Centre, Toronto
Registry updated 2026-10-27
NCT05623020
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Trial Treatment · Phase 3 · Pfizer
Arthur J.E. Child Comprehensive Cancer Centre, Calgary · Cross Cancer Institute, Edmonton · Dr. Everett Chalmers Regional Hospital, Fredericton · QEII Health Sciences Centre, Halifax · Nova Scotia Health Authority, Halifax · Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Univer, Sherbrooke · Princess Margaret Cancer Centre, Toronto
Registry updated 2026-10-27
NCT04973605
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Trial Treatment · Phase 1/2 · BeOne Medicines
Cross Cancer Institute, Edmonton · Princess Margaret Cancer Centre, Toronto · British Columbia Cancer Agency the Vancouver Centre, Vancouver
Registry updated 2026-10-26
NCT06280924
Prehab Prior to Stem Cell Transplantation in Multiple Myeloma
Trial Treatment · University of Alberta
University of Alberta - Cross Cancer Institute, Edmonton
Registry updated 2026-10-23
NCT05651932
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Trial Treatment · Phase 1 · K36 Therapeutics, Inc.
Cross Cancer Institute, Edmonton · University Health Network (UHN) - Princess Margaret Cancer Centre (Princess Margaret Hospital), Toronto
Registry updated 2026-10-22
NCT07735637
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
Trial Treatment · Phase 3 · AstraZeneca
Calgary · Halifax · Montreal · Sherbrooke
Registry updated 2026-10-21
NCT04910568
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
Trial Treatment · Phase 1 · Genentech, Inc.
Cross Cancer Institute, Edmonton · Hamilton Health Sciences, Hamilton · University Health Network, Toronto
Registry updated 2026-10-20
NCT06182774
Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma
Trial Treatment · Phase 3 · Canadian Cancer Trials Group
Royal Victoria Regional Health Centre, Barrie · William Osler Health System, Brampton · Cross Cancer Institute, Edmonton · Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton · BCCA - Kelowna, Kelowna · Kingston Health Sciences Centre, Kingston · Waterloo Regional Health Network (WRHN), Kitchener · London Health Sciences Centre Research Inc., London · Trillium Health Partners - Credit Valley Hospital, Mississauga · The Moncton Hospital, Moncton · The Jewish General Hospital, Montreal · St. Mary's Hospital, Montreal · The Research Institute of the McGill University, Montreal · CIUSSS de l'Est-de-I'lle-de-Montreal, Montreal · Stronach Regional Health Centre at Southlake, Newmarket · Oakville Trafalgar Memorial Hospital, Oakville · Lakeridge Health Oshawa, Oshawa · Ottawa Hospital Research Institute, Ottawa · CHU de Quebec-Hopital l'Enfant-Jesus (HEJ), Québec · Allan Blair Cancer Centre, Regina · Regional Health Authority B, Zone 2, Saint John · Saskatoon Cancer Centre, Saskatoon · Algoma District Cancer Program, Sault Ste. Marie · Niagara Health System, St. Catharines · Dr. H. Bliss Murphy Cancer Centre, St. John's · Thunder Bay Regional Health Sciences Centre, Thunder Bay · St. Michael's Hospital, Toronto · St. Joseph's Health Centre, Toronto · BCCA - Vancouver, Vancouver · Windsor Regional Cancer Centre, Windsor · CancerCare Manitoba, Winnipeg
Registry updated 2026-10-14
NCT07648264
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Trial Treatment · Phase 3 · CSL Behring
Horizon Health Network, Fredericton · McGill University Health Research Institute, Montreal
Registry updated 2026-10-14
NCT06980480
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Trial Treatment · Phase 3 · Takeda
Centre Hospitalier de l'Université de Montréal, Montreal · Cancer Care Manitoba, Winnipeg
Registry updated 2026-10-13
NCT07555938
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Trial Treatment · Phase 3 · Hoffmann-La Roche
Hamilton Health Sciences-Juravinski Cancer Centre, Hamilton
Registry updated 2026-10-13
NCT05243797
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Trial Treatment · Phase 3 · European Myeloma Network B.V.
Cross Cancer Institute, Edmonton · QEII Health Sciences Centre, Halifax · The Ottawa General Hospital, Ottawa · Saskatoon Cancer Center, Saskatoon · Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre hospitalier universitaire de Sherbrooke (CIUSSS de l'Estrie-CHUS), Sherbrooke · Princess Margaret Cancer Centre, Toronto · BC Cancer, Vancouver
Registry updated 2026-10-07
NCT05730036
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
Trial Treatment · Phase 3 · Regeneron Pharmaceuticals
The Ottawa Hospital Cancer Centre, Ottawa · Sunnybrook Health Sciences Centre, Toronto · University Health Network - Princess Margaret Cancer Center, Toronto
Registry updated 2026-10-07
NCT06297226
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Trial Treatment · Phase 2 · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Arthur J.E. Child Comprehensive Cancer Centre, Calgary · McGill University Health Centre, Montreal
Registry updated 2026-10-06
NCT06224309
Preliminary Assessment of [18F]BL40 in PET/CT Scans
Research · British Columbia Cancer Agency
BC Cancer, Vancouver
Registry updated 2026-10-01
NCT06871176
PET/MR Scan With [68Ga]Ga-PentixaFor (CXCR4) vs Standard of Care (SOC) for Initial Staging and Follow up in Multiple Myeloma (MM)
Trial Treatment · University Health Network, Toronto
University Health Network, Toronto
Registry updated 2026-10-01
NCT07391657
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Trial Treatment · Phase 3 · AstraZeneca
Calgary · Montreal · Toronto · Vancouver
Registry updated 2026-09-29
NCT06421675
Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma
Trial Treatment · Phase 2 · Ontario Clinical Oncology Group (OCOG)
Juravinski Cancer Center, Hamilton · Kingston General Hospital, Kingston · London Health Science Centre - Victoria Hospital, London · Ottawa Hospital, Ottawa · Vancouver Cancer Center, Vancouver · BC Cancer - Victoria, Victoria
Registry updated 2026-09-28
NCT03702309
Liquid Biopsy Evaluation and Repository Development at Princess Margaret
Research · University Health Network, Toronto
Princess Margaret Cancer Centre, Toronto
Registry updated 2026-09-25
NCT07518186
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Trial Treatment · Phase 3 · Janssen Research & Development, LLC
Arthur J.E. Child Comprehensive Cancer Centre, Calgary · Cross Cancer Institute, Edmonton · Lakeridge Health Oshawa, Oshawa · Princess Margaret Hospital, Toronto
Registry updated 2026-09-25

All Multiple myeloma trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error